Dan Ou1, Pierre Blanchard2, Clément El Khoury2, Francesca De Felice2, Caroline Even3, Antonin Levy2, France Nguyen2, François Janot3, Philippe Gorphe3, Eric Deutsch2, Stephane Temam3, Yungan Tao4. 1. Department of Radiation Oncology, Gustave Roussy, Paris-Saclay University, Villejuif, France; Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China. 2. Department of Radiation Oncology, Gustave Roussy, Paris-Saclay University, Villejuif, France. 3. Department of Head and Neck Oncology, Gustave Roussy, Paris-Saclay University, Villejuif, France. 4. Department of Radiation Oncology, Gustave Roussy, Paris-Saclay University, Villejuif, France. Electronic address: yungan.tao@gustaveroussy.fr.
Abstract
OBJECTIVES: To evaluate the efficacy of induction chemotherapy with docetaxel, cisplatin and fluorouracil (TPF) followed by concurrent chemoradiotherapy (IC+CCRT) or CCRT alone in non-endemic locally advanced nasopharyngeal carcinoma (NPC) patients. MATERIALS AND METHODS: Data of 106 patients with NPC treated from January 1999 to June 2012 with IC+CCRT (n=58) or CCRT alone (n=48) were retrospectively reviewed. RESULTS: Median follow-up was 6.4years. Distribution of age, performance status, stage and concurrent chemotherapy regimen were imbalanced between the two groups. The 5-year overall survival (OS) and progression-free survival (PFS) were not significantly different between IC+CCRT and CCRT groups (OS: 78.3% vs. 82.7%, p=0.77; PFS: 72.5% vs. 68.2%, p=0.81, respectively). There were less total cumulative incidence of grade 3-4 late radiation morbidity in the IC+CCRT group (44.8% vs. 70.8%, p=0.01). Five-year OS for patients with post-IC complete response (CR), partial response (PR) and stable disease (SD) sub-groups were 100%, 79.4% and 60%, respectively. CONCLUSION: Compared with CCRT alone, IC (TPF regimen)+CCRT did not improve OS or PFS in patients with NPC, but less grade 3-4 late toxicities were observed. Responsiveness of IC may provide additional prognostic information.
OBJECTIVES: To evaluate the efficacy of induction chemotherapy with docetaxel, cisplatin and fluorouracil (TPF) followed by concurrent chemoradiotherapy (IC+CCRT) or CCRT alone in non-endemic locally advanced nasopharyngeal carcinoma (NPC) patients. MATERIALS AND METHODS: Data of 106 patients with NPC treated from January 1999 to June 2012 with IC+CCRT (n=58) or CCRT alone (n=48) were retrospectively reviewed. RESULTS: Median follow-up was 6.4years. Distribution of age, performance status, stage and concurrent chemotherapy regimen were imbalanced between the two groups. The 5-year overall survival (OS) and progression-free survival (PFS) were not significantly different between IC+CCRT and CCRT groups (OS: 78.3% vs. 82.7%, p=0.77; PFS: 72.5% vs. 68.2%, p=0.81, respectively). There were less total cumulative incidence of grade 3-4 late radiation morbidity in the IC+CCRT group (44.8% vs. 70.8%, p=0.01). Five-year OS for patients with post-IC complete response (CR), partial response (PR) and stable disease (SD) sub-groups were 100%, 79.4% and 60%, respectively. CONCLUSION: Compared with CCRT alone, IC (TPF regimen)+CCRT did not improve OS or PFS in patients with NPC, but less grade 3-4 late toxicities were observed. Responsiveness of IC may provide additional prognostic information.
Authors: Wang Fangzheng; Jiang Chuner; Sun Quanquan; Ye Zhimin; Liu Tongxin; Liu Jiping; Masoto Sakamoto; Wu Peng; Shi Kaiyuan; Qin Weifeng; Fu Zhenfu; Jiang Yangming Journal: Oncotarget Date: 2017-12-14